XW0U0GA
Introduction Joints to New Technology Group 10 with Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System, Open Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | U Joints |
| Approach | 0 Open |
| Device | G Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System |
| Qualifier | A New Technology Group 10 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Joints
Introduction to joints as a body part covers delivery of a novel substance into a synovial joint space as a class, used when a New Technology agent, such as an investigational biologic or specialized lubricant, is injected to address cartilage degeneration or inflammatory joint disease. Joints are enclosed by a capsule and lined with synovium, which governs how injected material distributes and is retained, making the joint space a natural reservoir for locally acting agents. Because this code is not specific to a single joint like the knee or hip, documentation should confirm that the procedure targets joint tissue generally under the applicable New Technology group rather than a more granular articular structure. The emerging nature of these agents means outcomes tracking depends on precise, consistent code assignment across treated joints.
Approach: Open
Open approach in New Technology denotes access to the target site through a surgical incision that exposes the body part directly to view and instrumentation. It stands apart from percutaneous and endoscopic approaches, which achieve access through small punctures or existing openings rather than a deliberate surgical opening of tissue.
Device / Substance / Technology: Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System
This value identifies use of a temporary irrigation spacer system that elutes vancomycin hydrochloride and tobramycin sulfate, typically placed in a joint space after removal of an infected prosthesis to deliver local antibiotics while awaiting reimplantation. It differs from bone void fillers with antibiotic elution by functioning as a removable irrigation spacer device rather than a permanent or resorbable graft substitute.
Qualifier: New Technology Group 10
New Technology Group 10 flags a procedure as part of the 2023 batch of add-on codes recognized under the New Technology section. The value itself carries no information about the device or drug involved; that comes from the table, body part, and approach values alongside it. Coders should not confuse it with Group 9 or Group 11, which cover the cohorts approved in the years immediately before and after.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.